- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02056041
Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma
June 17, 2014 updated by: Prof. Guido Torzilli, University of Milan
Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma: Validation on 336 Consecutive Hepatectomies.
Selection criteria for safe hepatectomy for HCC are not well established.
The aim of this study was the validation of the selection criteria for safe hepatectomy for hepatocellular carcinoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
All consecutive patients submitted to hepatectomy for HCC based on the same preoperative selection criteria from our prospectively-maintained liver unit database.
Such criteria included the value of bilirubin (BIL), the value of cholinesterases (CHE), the presence of ascites, the presence of esophageal varices, and the rate of residual liver volume.
Study Type
Observational
Enrollment (Actual)
336
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rozzano, Milan, Italy, 20089
- Humanitas Research Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
The records of 336 consecutive patients who were submitted to hepatectomy between 2004-2012 were reviewed.
Description
Inclusion Criteria:
- any patient with HCC submitted to hepatic resection at our Unit in the established frame time
Exclusion Criteria:
- any patient with missing data or lost at follow-up
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Hepatectomy for HCC
Patients submitted to surgery for HCC
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of surgery for HCC
Time Frame: 90 days
|
The primary endpoint was the validation of our selection criteria for safe hepatectomy for HCC in regards to postoperative complications.
The role of total bilirubin and cholinesterases was analzyed together with other clinical parameters.
|
90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score systems HCC
Time Frame: 90 days
|
The secondary endpoint was the testing of the most common score systems for HCC, which are the CPT score, the MELD score, and the APRI score.
|
90 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
February 3, 2014
First Submitted That Met QC Criteria
February 4, 2014
First Posted (Estimate)
February 5, 2014
Study Record Updates
Last Update Posted (Estimate)
June 18, 2014
Last Update Submitted That Met QC Criteria
June 17, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SafeSurgeryHCC
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatectomy
-
University Hospital HeidelbergUnknown
-
Sir Run Run Shaw HospitalCompleted
-
Seoul National University HospitalCompleted
-
Hospital Italiano de Buenos AiresCompleted
-
Rennes University HospitalMinistry of Health, FranceCompleted
-
Xuyu ZhangRecruitingLaparoscopic HepatectomyChina
-
Klinikum Saarbrücken, Klinik für Allgemein-, Viszeral-...CompletedLaparoscopic HepatectomyGermany
-
Sun Yat-sen UniversityUnknownLaparoscopic HepatectomyChina
-
National Taiwan University HospitalUnknownRight HepatectomyTaiwan
-
Zhujiang HospitalNot yet recruitingHepatectomy | HepatolithiasisChina
Clinical Trials on Hepatectomy
-
Shuguo Zheng, MDCompleted
-
Sun Yat-sen UniversityMinistry of Health, ChinaCompletedHepatocellular Carcinoma | Hepatectomy | ChemoembolizationChina
-
Sun Yat-sen UniversityCompletedHepatocellular CarcinomaChina
-
Samsung Medical CenterCompletedHealthy Donors for Liver TransplantationKorea, Republic of
-
Chinese PLA General HospitalThe First Hospital of Jilin UniversityRecruitingHepatocellular Carcinoma Stage IIIChina
-
China Medical University HospitalMinistry of Health and Welfare, Taiwan; An-Nan Hospital, China Medical UniversityCompletedSurgery--Complications | Postoperative Hemorrhage | Gastrointestinal HemorrhageTaiwan
-
Wuhan Union Hospital, ChinaRecruiting
-
Southwest Hospital, ChinaUnknownHepatocellular CarcinomaChina
-
Southwest Hospital, ChinaUnknownHepatocellular Carcinoma | CirrhosisChina